Dyadic Intl Inc Del Stock Price, News & Analysis

Dyadic International, a biotechnology firm (NASDAQ: DYAI), announced it will report its 2021 financial results and host a corporate update conference call on March 29, 2022. The company is focused on its proprietary C1-cell protein platform, which aims to lower production costs and enhance biologic vaccine and drug development. The conference will be accessible via dial-in or webcast, providing shareholders an opportunity to stay informed about the company's operations and future prospects.

Dyadic International and Phibro Animal Health have entered an exclusive license agreement to utilize Dyadic's C1-cell protein production platform for developing a poultry vaccine targeting a specific disease. This partnership follows successful proof of concept animal trials. The agreement allows Phibro to produce targeted antigens for vaccine commercialization. Both companies plan to continue their collaboration to develop additional animal vaccine candidates, thereby enhancing the efficiency of vaccine production.

Dyadic International (NASDAQ: DYAI), a global biotechnology company, announced that CEO Mark Emalfarb will present at the 2022 BIO CEO & Investor Conference on February 14-15, 2022. His presentation, titled “Revolutionary C1 Protein Production Platform”, focuses on improving vaccine and therapeutic access through innovative technology. The presentation will be available on demand during the conference. Dyadic aims to leverage its proprietary C1-cell protein production platform to enhance biologic vaccines and drugs, making them more affordable and accessible.

Dyadic International (NASDAQ: DYAI) has engineered its C1-cells to produce therapeutically viable cannabis compounds, including cannabidiol (CBD), enhancing production efficiency. This innovative approach could lower costs and improve product purity compared to traditional extraction from Cannabis sativa. The company emphasizes environmental benefits and potential medical applications of cannabinoids, such as therapeutic effects on inflammation and viral infections like coronavirus. Dyadic aims to leverage this technology as part of a broader strategic plan focusing on human and animal health.

Dyadic International, Inc. (NASDAQ: DYAI) has been awarded a project grant of up to $690,000 from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) through the American Rescue Plan. This funding aims to enhance Dyadic's proprietary C1 thermophilic fungal protein production platform to develop antibodies. The project will benchmark the platform's speed compared to traditional methods, aiming to improve public health responses to future pandemics.

Dyadic International (NASDAQ: DYAI) announced a strategic collaboration with Janssen Biotech to utilize its C1-cell protein production platform. Janssen will pay Dyadic an upfront fee of $500,000 and provide up to €1.6 million for R&D. The agreement includes potential mid-seven figure payments for exclusive licenses and additional milestone payments based on product development. This partnership aims to enhance therapeutic protein development, showcasing Dyadic's expanding role in biopharmaceuticals.

Dyadic International (NASDAQ: DYAI) advances its COVID-19 vaccine candidate, DYAI-100, towards first-in-human trials. The company reported $22.8 million in cash as of September 30, 2021, down from $29.2 million at year-end 2020. R&D revenue rose to $693,000, while R&D expenses surged to $1.9 million for Q3 2021, driven by the clinical trial costs for DYAI-100. Dyadic has also engaged in new R&D collaborations and enhanced its leadership team with the appointment of Joseph Hazelton as Chief Business Officer. The net loss narrowed to $1.7 million, or $(0.06) per share.

Dyadic International has appointed Joe Hazelton as Chief Business Officer, effective immediately, to enhance global commercialization of its C1-cell protein production platform. This strategic move aims to support new and existing business initiatives, including corporate strategy and licensing. Mr. Hazelton, with over 20 years in the pharmaceutical industry, will lead efforts to maximize the integration of the C1 technology across various sectors, targeting the expanding biologic markets and animal health segments.

Dyadic International will report its Q3 2021 financial results on November 10, 2021. The company focuses on its proprietary C1-cell protein production platform aimed at enhancing biologic vaccine and drug development. This platform is designed to lower production costs and improve performance. Investors can join a conference call at 5:00 PM ET to discuss these results and the company's future outlook. The C1 technology utilizes the fungus Thermothelomyces heterothallica to produce low-cost proteins efficiently.